Results 41 to 50 of about 18,962 (231)
Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment
Current Issues in Molecular Biology, 2023 Diabetes mellitus is a chronic multisystem disease with a high global prevalence. The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to lower glucose levels and reduce weight.
Mohamed Rafiullah +6 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching +2 more
wiley +1 more source
Saudi Pharmaceutical JournalLiraglutide, a type2 diabetes mellitus (T2DM)-related treatment, improves glycemic control and reduces the risks of adverse cardiovascular events in T2DM patients.
Hicham Benabdelkamel +5 more
doaj +1 more source
A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats [PDF]
PeerJ, 2019 Background and Aims Many studies have revealed that glucagon-like peptide-1 has vasoprotective effects. In this study, we investigated whether liraglutide suppressed endothelial dysfunction and explored the mechanism involved.
Qian Zhang +3 more
doaj +2 more sources
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway
International Journal of Endocrinology, 2020 Liraglutide is a glucagon-like peptide-1 analogue widely used in the treatment of type 2 diabetes mellitus. However, the effects of liraglutide on osteoblast proliferation and differentiation in MC3T3-E1 cells have not been fully elucidated.
Yue Sun +3 more
doaj +1 more source
Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet [PDF]
Brazilian Archives of Biology and Technology, 2019 The objective of this study was to evaluate the effect of liraglutide, an analog of glucagon-like peptide-1 (GLP-1) in association with physical exercise, on the metabolic and biochemical parameters of rats induced to obesity with a cafeteria diet.
Daiane Didek +8 more
doaj +1 more source
Obesity, EarlyView.ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo +4 more
wiley +1 more source
Clinical and Experimental Hypertension, 2020 The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients.
Di Zhao, Hui Liu, Pingshuan Dong
doaj +1 more source
Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats
Endocrinology, Diabetes & Metabolism, 2023 Introduction The incretin hormone glucagon‐like peptide‐1 (GLP‐1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP‐1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and ...
Michael M. Swarbrick +6 more
doaj +1 more source